BDDE Crosslinked Hyaluronic Acid Gel Without Surfactant Instability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing hyaluronic acid treatments for osteoarthritis have short-term efficacy due to rapid degradation and uneven dispersion of corticosteroids, leading to instability and reduced therapeutic effect.
Innovation Solution
A method involving the crosslinking of hyaluronic acid with triamcinolone using 1,4-butanediol diglycidyl ether (BDDE) to form a gel that ensures even dispersion and sustained release of triamcinolone, eliminating the need for surfactants like polysorbate 80, thereby enhancing stability and prolonging therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If linear hyaluronic acid is used for injection, then the injection process is simple, but the degradation time is short and therapeutic effect duration is limited
Solution Approach 1:
The patent combines hyaluronic acid with crosslinking agents (BDDE, genipin, or glutaraldehyde) to create a composite crosslinked hydrogel structure. This composite material maintains the biocompatibility of hyaluronic acid while adding crosslinked network structures that resist degradation, thereby extending therapeutic effect duration from weeks to months while preserving injectability
2Reliability
If corticosteroids are added to hyaluronic acid formulation, then anti-inflammatory effect is enhanced, but uneven dispersion occurs leading to instability
Solution Approach 1:
The patent uses surfactants (polysorbate 80, poloxamer 407, or lecithin) as intermediary substances to mediate between the hydrophobic corticosteroids and the hydrophilic hyaluronic acid matrix. These surfactants reduce interfacial tension and prevent aggregation, ensuring uniform dispersion of corticosteroids throughout the formulation while maintaining overall composition stability
3Duration of action of moving object
If crosslinked hyaluronic acid is used, then degradation time is prolonged and therapeutic effect duration is extended, but the manufacturing process becomes more complex
Solution Approach 1:
The patent performs crosslinking reactions during the manufacturing process itself, using water-soluble crosslinking agents that react with hyaluronic acid under controlled conditions to pre-form the crosslinked network structure before injection. This preliminary crosslinking action extends degradation time while keeping the manufacturing process integrated and manageable
4Stability of the object's composition
If surfactants like polysorbate 80 are used for corticosteroid dispersion, then dispersion uniformity is improved, but product stability is reduced due to surfactant-related issues
Solution Approach 1:
The patent modifies the chemical parameters of the formulation by selecting surfactants with specific properties (HLB values, molecular weights, and chemical structures) that provide optimal dispersion uniformity while maintaining long-term product stability. The patent also optimizes surfactant concentrations and pH conditions to achieve the desired balance between dispersion quality and formulation stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crosslinked hyaluronic acid gel provides a sustained-release effect for triamcinolone, offering prolonged anti-inflammatory and analgesic benefits for osteoarthritis treatment without surfactant-related instability, suitable for intra-articular injection.
Implementation Method 1
crosslinking the colloid of step (b) with 1,4-butanediol diglycidyl ether (BDDE)
Data Source
Figure 1~2
Figure 3
AI summary
The present disclosure provides a method for manufacturing a crosslinked hyaluronic acid gel and a crosslinked hyaluronic acid gel. The crosslinked hyaluronic acid gel contains substantially evenly distributed triamcinolone.